SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Pérez-Segura, Pedro (Hospital Clínico San Carlos (Madrid))
Vilariño, Noelia (Hospital Universitari de Bellvitge)
Martínez García, María (Hospital del Mar (Barcelona, Catalunya))
Del Barco Berrón, Sonia (Hospital Universitari de Girona Doctor Josep Trueta)
Gironés, Regina (Hospital Universitari i Politècnic La Fe (València))
García Gómez, Jesús (Complexo Hospitalario Universitario de Ourense - CHUO)
García Castaño, Almudena (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Navarro Martín, Luis Miguel (Complejo Asistencial Universitario de Salamanca)
Gallego Rubio, Oriol (Institut d'Investigació Biomèdica Sant Pau)
Pineda, Estela (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Epidemiology ; High-grade gliomas ; Management ; Molecular ; Treatment
Published in:	Clinical & translational oncology, Vol. 25 Núm. 9 (september 2023) , p. 2634-2646, ISSN 1699-3055

DOI: 10.1007/s12094-023-03245-y
PMID: 37540408

13 p, 770.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles